Peter Thiel-backed psychedelics player ATAI pulls in another nine-figure raise. But they're not ready to talk IPO — yet
Roughly three and a half months since its last fundraising round, the Peter Thiel-backed ATAI Life Sciences has pulled in its latest venture haul.
The company closed a $157 million Series D round early Wednesday as it presses the gas on its psychedelics-based strategy. Though the short time between the two raises will likely fuel speculation about a potential jump to Nasdaq, ATAI isn’t ready to talk about that just yet, preemptively declining comment on all IPO-related questions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.